JPWO2021231854A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021231854A5 JPWO2021231854A5 JP2022568830A JP2022568830A JPWO2021231854A5 JP WO2021231854 A5 JPWO2021231854 A5 JP WO2021231854A5 JP 2022568830 A JP2022568830 A JP 2022568830A JP 2022568830 A JP2022568830 A JP 2022568830A JP WO2021231854 A5 JPWO2021231854 A5 JP WO2021231854A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- peg
- lnp
- lipid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091033319 polynucleotide Proteins 0.000 claims 41
- 102000040430 polynucleotide Human genes 0.000 claims 41
- 239000002157 polynucleotide Substances 0.000 claims 41
- 239000000203 mixture Substances 0.000 claims 39
- 150000002632 lipids Chemical class 0.000 claims 29
- 238000000034 method Methods 0.000 claims 19
- -1 amino lipid Chemical class 0.000 claims 17
- 230000027455 binding Effects 0.000 claims 15
- 239000012636 effector Substances 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 11
- 101000941029 Homo sapiens Endoplasmic reticulum junction formation protein lunapark Proteins 0.000 claims 10
- 101000991410 Homo sapiens Nucleolar and spindle-associated protein 1 Proteins 0.000 claims 10
- 102100030991 Nucleolar and spindle-associated protein 1 Human genes 0.000 claims 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 101710091919 Eukaryotic translation initiation factor 4G Proteins 0.000 claims 7
- 108020004999 messenger RNA Proteins 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 150000003904 phospholipids Chemical class 0.000 claims 6
- 230000000069 prophylactic effect Effects 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 238000007385 chemical modification Methods 0.000 claims 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 4
- 125000002091 cationic group Chemical group 0.000 claims 4
- 235000012000 cholesterol Nutrition 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000007115 recruitment Effects 0.000 claims 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 4
- 101001008442 Homo sapiens La-related protein 7 Proteins 0.000 claims 3
- 102100027436 La-related protein 7 Human genes 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 238000011144 upstream manufacturing Methods 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 2
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 229930182558 Sterol Natural products 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 229940087168 alpha tocopherol Drugs 0.000 claims 2
- 229940076810 beta sitosterol Drugs 0.000 claims 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims 2
- 150000001783 ceramides Chemical class 0.000 claims 2
- 229940107161 cholesterol Drugs 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 150000001982 diacylglycerols Chemical class 0.000 claims 2
- 125000005265 dialkylamine group Chemical class 0.000 claims 2
- 150000001985 dialkylglycerols Chemical class 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 150000008103 phosphatidic acids Chemical class 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims 2
- 229950005143 sitosterol Drugs 0.000 claims 2
- 150000003432 sterols Chemical class 0.000 claims 2
- 235000003702 sterols Nutrition 0.000 claims 2
- 229960000984 tocofersolan Drugs 0.000 claims 2
- 239000002076 α-tocopherol Substances 0.000 claims 2
- 235000004835 α-tocopherol Nutrition 0.000 claims 2
- KYEKLQMDNZPEFU-KVTDHHQDSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)N=C1 KYEKLQMDNZPEFU-KVTDHHQDSA-N 0.000 claims 1
- MUSPKJVFRAYWAR-XVFCMESISA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)S[C@H]1N1C(=O)NC(=O)C=C1 MUSPKJVFRAYWAR-XVFCMESISA-N 0.000 claims 1
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims 1
- SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 claims 1
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 claims 1
- JCNGYIGHEUKAHK-DWJKKKFUSA-N 2-Thio-1-methyl-1-deazapseudouridine Chemical compound CC1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O JCNGYIGHEUKAHK-DWJKKKFUSA-N 0.000 claims 1
- BVLGKOVALHRKNM-XUTVFYLZSA-N 2-Thio-1-methylpseudouridine Chemical compound CN1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O BVLGKOVALHRKNM-XUTVFYLZSA-N 0.000 claims 1
- CWXIOHYALLRNSZ-JWMKEVCDSA-N 2-Thiodihydropseudouridine Chemical compound C1C(C(=O)NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O CWXIOHYALLRNSZ-JWMKEVCDSA-N 0.000 claims 1
- JUMHLCXWYQVTLL-KVTDHHQDSA-N 2-thio-5-aza-uridine Chemical compound [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C(=S)NC(=O)N=C1 JUMHLCXWYQVTLL-KVTDHHQDSA-N 0.000 claims 1
- VRVXMIJPUBNPGH-XVFCMESISA-N 2-thio-dihydrouridine Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(=O)NC1=S VRVXMIJPUBNPGH-XVFCMESISA-N 0.000 claims 1
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 claims 1
- FGFVODMBKZRMMW-XUTVFYLZSA-N 4-Methoxy-2-thiopseudouridine Chemical compound COC1=C(C=NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O FGFVODMBKZRMMW-XUTVFYLZSA-N 0.000 claims 1
- HOCJTJWYMOSXMU-XUTVFYLZSA-N 4-Methoxypseudouridine Chemical compound COC1=C(C=NC(=O)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O HOCJTJWYMOSXMU-XUTVFYLZSA-N 0.000 claims 1
- VTGBLFNEDHVUQA-XUTVFYLZSA-N 4-Thio-1-methyl-pseudouridine Chemical compound S=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 VTGBLFNEDHVUQA-XUTVFYLZSA-N 0.000 claims 1
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 1
- DDHOXEOVAJVODV-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=S)NC1=O DDHOXEOVAJVODV-GBNDHIKLSA-N 0.000 claims 1
- BNAWMJKJLNJZFU-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidene-1h-pyrimidin-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=S BNAWMJKJLNJZFU-GBNDHIKLSA-N 0.000 claims 1
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 claims 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101150090523 DAZL gene Proteins 0.000 claims 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 claims 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 claims 1
- YKWUPFSEFXSGRT-JWMKEVCDSA-N Dihydropseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1C(=O)NC(=O)NC1 YKWUPFSEFXSGRT-JWMKEVCDSA-N 0.000 claims 1
- 102100029776 Eukaryotic translation initiation factor 3 subunit D Human genes 0.000 claims 1
- 101710109042 Eukaryotic translation initiation factor 3 subunit D Proteins 0.000 claims 1
- 101000735431 Homo sapiens Terminal nucleotidyltransferase 4A Proteins 0.000 claims 1
- 101000735429 Homo sapiens Terminal nucleotidyltransferase 4B Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108090000301 Membrane transport proteins Proteins 0.000 claims 1
- 102000003939 Membrane transport proteins Human genes 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 229930185560 Pseudouridine Natural products 0.000 claims 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims 1
- 102000015097 RNA Splicing Factors Human genes 0.000 claims 1
- 108010039259 RNA Splicing Factors Proteins 0.000 claims 1
- 238000010357 RNA editing Methods 0.000 claims 1
- 230000014632 RNA localization Effects 0.000 claims 1
- 230000026279 RNA modification Effects 0.000 claims 1
- 230000021839 RNA stabilization Effects 0.000 claims 1
- 230000004570 RNA-binding Effects 0.000 claims 1
- 101710172711 Structural protein Proteins 0.000 claims 1
- 102100034939 Terminal nucleotidyltransferase 4A Human genes 0.000 claims 1
- 102100034938 Terminal nucleotidyltransferase 4B Human genes 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 101150037035 tent2 gene Proteins 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063024862P | 2020-05-14 | 2020-05-14 | |
| US63/024,862 | 2020-05-14 | ||
| US202163183119P | 2021-05-03 | 2021-05-03 | |
| US63/183,119 | 2021-05-03 | ||
| PCT/US2021/032438 WO2021231854A1 (en) | 2020-05-14 | 2021-05-14 | Lnp compositions comprising an mrna therapeutic and an effector molecule |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023526059A JP2023526059A (ja) | 2023-06-20 |
| JP2023526059A5 JP2023526059A5 (https=) | 2024-05-24 |
| JPWO2021231854A5 true JPWO2021231854A5 (https=) | 2024-05-24 |
Family
ID=76284222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568830A Pending JP2023526059A (ja) | 2020-05-14 | 2021-05-14 | ｍＲＮＡ治療薬及びエフェクター分子を含むＬＮＰ組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230173104A1 (https=) |
| EP (1) | EP4149435A1 (https=) |
| JP (1) | JP2023526059A (https=) |
| AU (1) | AU2021270587A1 (https=) |
| CA (1) | CA3182920A1 (https=) |
| WO (1) | WO2021231854A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260035707A1 (en) * | 2022-07-26 | 2026-02-05 | Modernatx, Inc. | Engineered polynucleotides for temporal control of expression |
| CN115869332A (zh) * | 2022-10-27 | 2023-03-31 | 北京新合睿恩生物医疗科技有限公司 | 递送至体内后在肝脏少表达的mRNA药物及其制备方法 |
| EP4637786A2 (en) * | 2022-12-22 | 2025-10-29 | ModernaTX, Inc. | Small nuclear ribonucleoprotein 13 polypeptides, polynucleotides, and uses thereof |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025116441A1 (ko) * | 2023-11-30 | 2025-06-05 | 주식회사 레나임 | 골관절염의 예방 또는 치료용 약제학적 조성물 |
| WO2025255510A1 (en) * | 2024-06-07 | 2025-12-11 | The University Of Chicago | Systems and methods for modulating rna |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8613481D0 (en) | 1986-06-04 | 1986-07-09 | Diatech Ltd | Translation of mrna |
| JPH09505474A (ja) | 1993-11-26 | 1997-06-03 | ブリテイツシユ・テクノロジー・グループ・リミテツド | 翻訳エンハンサーｄｎａ |
| US5824497A (en) | 1995-02-10 | 1998-10-20 | Mcmaster University | High efficiency translation of mRNA molecules |
| EP2390331B1 (en) | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| DK2205618T3 (en) | 2007-09-26 | 2017-02-20 | Intrexon Corp | SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION |
| CA2722183C (en) | 2008-04-25 | 2018-09-18 | Northwestern University | Nanostructures suitable for sequestering cholesterol and other molecules |
| US9217155B2 (en) * | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| MX342785B (es) | 2009-06-10 | 2016-10-12 | Alnylam Pharmaceuticals Inc | Formulacion mejorada de lipido. |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| WO2013013013A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for producing modified glycoproteins |
| US9163706B2 (en) | 2012-08-29 | 2015-10-20 | Greg SEBLANTE, SR. | Sprocket box for increasing the gas mileage of a vehicle with an automatic transmission |
| US20140200261A1 (en) | 2013-01-17 | 2014-07-17 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| US20160052352A1 (en) | 2014-08-21 | 2016-02-25 | The Goodyear Tire & Rubber Company | Method of adhesion of rigid components to a tire |
| US9259829B1 (en) | 2014-08-25 | 2016-02-16 | Cougar Holdings, Llc | Roofing and nail removal hammer |
| EP3458474B1 (en) | 2016-05-18 | 2022-07-06 | ModernaTX, Inc. | Combinations of mrnas encoding immune modulating polypeptides and uses thereof |
| GB2568255A (en) * | 2017-11-08 | 2019-05-15 | Evox Therapeutics Ltd | Exosomes comprising RNA therapeutics |
| US20230081530A1 (en) * | 2018-09-14 | 2023-03-16 | Modernatx, Inc. | Methods and compositions for treating cancer using mrna therapeutics |
-
2021
- 2021-05-14 JP JP2022568830A patent/JP2023526059A/ja active Pending
- 2021-05-14 WO PCT/US2021/032438 patent/WO2021231854A1/en not_active Ceased
- 2021-05-14 AU AU2021270587A patent/AU2021270587A1/en not_active Abandoned
- 2021-05-14 US US17/924,456 patent/US20230173104A1/en active Pending
- 2021-05-14 CA CA3182920A patent/CA3182920A1/en active Pending
- 2021-05-14 EP EP21730410.4A patent/EP4149435A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112384205B (zh) | 信使rna疫苗及其用途 | |
| Frezard | Liposomes: from biophysics to the design of peptide vaccines | |
| EP0773295B1 (en) | Method for expressing polypeptides in fish by immersion in DNA-plasmid solution | |
| JPWO2021183563A5 (https=) | ||
| CN120204165A (zh) | 脂质纳米颗粒 | |
| JP7789103B2 (ja) | 原発性線毛機能不全症の治療のための組成物および方法 | |
| WO2024012272A1 (zh) | 脂质化合物及其应用 | |
| CN119095613A (zh) | 莱姆病rna疫苗 | |
| JPWO2021231854A5 (https=) | ||
| US20240390483A1 (en) | Mucosal messenger rna vaccine | |
| JPWO2021262909A5 (https=) | ||
| WO2024108740A1 (zh) | 适合于肌注给药的核酸-脂质纳米颗粒、制剂及其应用 | |
| WO2023050003A1 (en) | Compositions and methods for the prevention and/or treatment of covid-19 | |
| TW202530174A (zh) | 用於遞送的脂質化合物及脂質奈米顆粒 | |
| JPWO2019204666A5 (https=) | ||
| JP2025529906A (ja) | コロナウイルスに対するワクチン | |
| JPWO2023069498A5 (https=) | ||
| JPWO2023111262A5 (https=) | ||
| TW202440929A (zh) | 用於感染性疾病的組合物和方法 | |
| TW202444745A (zh) | 用於治療疾病的組合物和方法 | |
| WO2024073848A1 (en) | Compositions and methods for the prevention and/or treatment of covid-19 | |
| RU2024116295A (ru) | Композиции полинуклеотидов и их применения | |
| CN121909041A (zh) | 用于动物健康的rna疫苗 | |
| JP2025511756A (ja) | ワクチン及び関連する方法 | |
| CA3154578A1 (en) | Compositions and methods for the prevention and/or treatment of covid-19 |